showed that epratuzumab (humanized anti-CD22 antibody), currently in clinical trials for B-cell lymphomas and autoimmune diseases, induced the reduction of multiple B-cell antigen receptor-modulating proteins (CD19, CD21, and CD79b) on the surface of B cells via their trogocytosis to effector cells. The gene discussed is CD22; the disease is autoimmune disease.